Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

28.52
+1.866.98%
Post-market: 29.490.9700+3.40%17:35 EDT
Volume:1.33M
Turnover:37.80M
Market Cap:3.43B
PE:-9.87
High:29.36
Open:26.26
Low:26.01
Close:26.66
Loading ...

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 Fortitude™ Trial for Delpacibart Braxlosiran (Del-Brax) in People Living With Facioscapulohumeral Muscular Dystrophy

THOMSON REUTERS
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

Circio Advances RNA Platform and Strengthens Financial Position

TIPRANKS
·
26 Mar

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
22 Mar

Avidity Biosciences’ Promising Developments in DMD Treatment and Strategic Preparations for Future Success

TIPRANKS
·
19 Mar

Buy Rating for Avidity Biosciences Driven by Strategic Leadership and Patient-Centric Approach

TIPRANKS
·
19 Mar

Avidity Biosciences Price Target Maintained With a $72.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Press Release: Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
18 Mar

Optimistic Buy Rating for Avidity Biosciences Driven by Promising DMD Treatment and Strategic Expansion Plans

TIPRANKS
·
18 Mar

Promising Trial Results and Strong Growth Potential Lead to Buy Rating for Avidity Biosciences

TIPRANKS
·
18 Mar

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
17 Mar

Sector Update: Health Care Stocks Decline Premarket Monday

MT Newswires Live
·
17 Mar

Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD

MT Newswires Live
·
17 Mar

Avidity Biosciences Announces Positive EXPLORE44 Trial Results

TIPRANKS
·
17 Mar

BRIEF-Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial

Reuters
·
17 Mar

Avidity Biosciences Inc - on Track for Year-End 2025 Bla Submission for Del-Zota in Dmd44

THOMSON REUTERS
·
17 Mar

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

GlobeNewswire
·
14 Mar

Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target

MT Newswires Live
·
13 Mar

ProQR Announces Year End 2024 Operating and Financial Results

GlobeNewswire
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar